Last reviewed · How we verify
Self-administered prescription
The drug, a self-administered prescription medication developed by the McGill University Health Centre/Research Institute of the McGill University Health Centre, is currently marketed but lacks a specified primary indication or revenue data. A key strength is the protection offered by the key composition patent, which expires in 2028. The primary risk is the unspecified competitive landscape, which may pose challenges to market share and profitability.
At a glance
| Generic name | Self-administered prescription |
|---|---|
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform (NA)
- Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program (NA)
- The Back Pain Consortium Research Program Study (PHASE4)
- Computerized PAINRelieveIt Protocol for Cancer Pain Control in Hospice (NA)
- Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain (NA)
- Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain (NA)
- Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity (PHASE2)
- Combined Qigong and Acupressure for Improving Chemotherapy-induced Peripheral Neuropathy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: